# Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.

> **NCT03571230** · PHASE4 · UNKNOWN · sponsor: **Shandong University** · enrollment: 400 (estimated)

## Conditions studied

- Helicobacter Pylori Infection
- Antimicrobial Susceptibility Testing

## Interventions

- **DRUG:** two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)
- **DRUG:** two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)
- **DRUG:** one proton pump inhibitor(PPI)
- **DRUG:** Colloidal Bismuth Pectin
- **DRUG:** two antibiotics for failed eradication(tetracyclin,furazolidone)

## Key facts

- **NCT ID:** NCT03571230
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-01
- **Primary completion:** 2019-12-30
- **Final completion:** 2020-01-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03571230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03571230, "Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03571230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*